Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab alone or with cisplatin + fluorouracil versus placebo + cisplatin + fluorouracil in first-line advanced gastric or gastroesophageal junction adenocarcinoma
2015-000972-88Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Merck & Co. Primary endpoint: Efficacy endpoints. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2015-000972-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000972-88.